



April 10, 2020

Christian Bixby,  
Assistant Director, Research and Clinical Lab Services, RUCDR  
Rutgers Clinical Genomics Laboratory-Rutgers University  
604 Allison Road,  
Piscataway, NJ 08854 US

Re: EUA200090  
Trade/Device Name: ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit  
Laboratory: Rutgers Clinical Genomics Laboratory-Rutgers University  
Dated: March 28, 2020  
Received: March 30, 2020

Dear Christian Bixby:

This letter is in response to your request that the Food and Drug Administration (FDA) add your test as an authorized test to the March 31, 2020 Emergency Use Authorization (EUA), pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). We have reviewed the EUA submission package and determined that your test meets the criteria for issuance under section 564(c) of the Act because your test is eligible for authorization under the March 31, 2020 EUA for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). As such, your test is hereby added to Appendix A<sup>1</sup> as an authorized test.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am adding this test to Appendix A as an authorized test, as described in the Scope of Authorization (Section II) and pursuant to the Conditions of Authorization (Section IV) of the attached letter of authorization<sup>2</sup> for use by the authorized laboratory to detect SARS-CoV-2 in specimens collected from individuals suspected of COVID-19 by their healthcare provider. Accordingly, in addition to this letter, you will receive copies of the FDA Letter of Authorization and the authorized Healthcare Provider and Patient Fact Sheets that must be used in conjunction with your authorized test pursuant to the Conditions of Authorization (Section IV) of the Letter of Authorization.

Sincerely yours,

---

Uwe Scherf, M.Sc., Ph.D.  
Director, Division of Microbiology Devices  
OHT7: Office of In Vitro Diagnostics and Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

---

<sup>1</sup> Appendix A is available at, <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>.

<sup>2</sup> The Letter of Authorization is available at, <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>.